At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma not amenable to curative surgery
- ✓Extensive disease (distant, pleural, pulmonary with/without mediastinal, or recurrent progressive disease in prior radiotherapy site)
- ✓Measurable disease required
- ✓Age 18 years or older
- ✕Acute concurrent complications (infection, post-surgical complications)
- ✕Other prior malignancy within past 5 years unless curatively treated with no recurrence
- ✕Prior chemotherapy for metastatic disease (prior neoadjuvant/adjuvant allowed if >1 year disease-free interval)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
In Brief
A Phase 2 clinical trial evaluating carboplatin and paclitaxel for Thymoma and Thymic Carcinoma. Completed, enrolled 46 participants across 67 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patients who have advanced thymoma.
Study Details
Timeline
Interventions
Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles